We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > entrectinib

News List

Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents worldpharmanews
May 21, 2019
Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents.
Two new cancer Priority Reviews for Roche pharmaphorum
February 20, 2019
Roche has announced that the FDA has granted Priority Review to two of its drugs – personalised lung cancer medicine entrectinib and lymphoma treatment polatuzumab vedotin.
Genentech gets FDA priority review for two cancer drugs pharmaceutical-technology
February 20, 2019
Genentech, a subsidiary of Roche, has secured priority review status from the US Food and Drug Administration (FDA) for two of its oncology drugs, entrectinib and polatuzumab vedotin.
PRIME status for Ignyta’s entrectinib pharmatimes
October 19, 2017
European regulators have awarded Ignyta’s cancer drug entrectinib Priority Medicines (PRIME) designation, potentially placing the treatment on a faster path to approval.